Kornimate/medical-research-clean huggingface dataset:
bio-psycho-social pathways underlying the effects of qigong among comorbid depressed elderly with chronic conditions

Conditions: Chronic Disease; Depressive Symptoms

Summary: depression and chronic medical conditions are common in older adults. qigong is increasingly documented to have anti-depressive effects for older adults. nevertheless, the scientific concepts behind qigong remain a mystery. to fill the knowledge gap, the neurobiological mechanism of the effects of qigong was explored. in addition, the benefits of qigong on subjective well-being, functional independence, sleep quality, mobility, and muscle strength were also tested. after random assignment, intervention group (n = 14) went through individual qigong exercise twice a week and for 12 weeks,whereas control group (n = 16) was involved in cognitive training activities with mobilization elements. the psychosocial, physical, and neurobiological outcomes of the two groups were compared.


Eligibility criteria:
inclusion criteria: * aged 60 or above * have been suffering from chronic medical conditions for more than one year * have depressive symptoms as indicated by geriatric depression scale (gds ≥ 6) exclusion criteria: * have practiced or received training of any form of mind-body exercises (including tai chi, yoga, and qigong) during the 6 months prior to intervention. * have changed medication or the dosage prior to or during intervention * have obvious cognitive and language impairment or score less than 20 in mini-mental state examination (mmse) * undergo electroconvulsive therapy, psychotherapy, or psychoeducation * cannot demonstrate satisfactory sitting balance
a modified behavioral activation treatment for geriatric depressive symptoms in left-behind elderly in rural china

Conditions: Health Behavior; Depression

Summary: background: it is essential to understand how to prevent and treat the epidemic of depression. several studies have reported the prevalence of depressive symptoms in the urban population in china, but there is a lack of information regarding intervention for depression in rural left behind old elderly people. objective: to evaluate the effectiveness of a modified behavioral activation treatment (mbat) intervention on reducing depressive symptoms in rural left behind elderly people. methods: 80 rural left behind elderly people who had a geriatric depression scale(gds) score between 11 and 25 will be recruited and randomly assigned to the intervention (n=40) and control group(n=40). the intervention group will be received both mbat and treatment-as-usual for 8 weeks while the control group received treatment-as-usual. both groups will be assessed with the gds, beck anxiety inventory (bai), and oxford happiness questionnaire (ohq) at baseline, immediately post-intervention, and at 3 months post-intervention. significance: this is the first time ba psychotherapy will be used in china.the current study will develop an intention model based on the traditional ba and cbt. the recurrence and seriousness of depression symptoms may be reduced by the intervention program. we hope that mbat in clients will provide a direction for the management of mental health in rural left-behind elders..


Eligibility criteria:
inclusion criteria: * over 65 years of age; * only one participant from each family; * left-behind for longer than 6 months; * gds score between 11 and 25. exclusion criteria: * psychiatric and medical comorbidities that are potentially life threatening or expected to severely limit client participation or adherence; * those who are currently seeing a cognitive behavioral therapist, psychotherapist or counselor; * people unable to understand and fill out the questionnaires.
immune adsorption role in treatment of resistant lupus

Conditions: Systemic Lupus

Summary: background: lupus is a heterogeneous autoimmune disease with autoantibodies formation. lupus nephritis carries the worst prognosis. c1q deficiency correlates with activity and renal involvement and may help in its evaluation. therapies include plasma exchange, immune adsorption and recently under evaluation, hemodiafiltration with on-line endogenous re infusion (hfr), in addition to traditional immunosuppressive therapies. aim: is to evaluate the role of hfr in improving signs and symptoms of sle activity and laboratory parameters not responding to traditional immune suppressive therapy

settings and design: a controlled clinical study was conducted on group a, sixty patients with lupus in activity subdivided into cases 1, 47 patients, who received traditional medical treatment and cases 2 group, 13 patients, who underwent hfr in addition to medical treatment. and group b that consisted of two subgroups, control 1, 20 healthy age and sex matched volunteers and control 2, 10 cases with different glomerular diseases other than lupus. methods and materials: serum c1q was done before and after the hfr as well as induction by medical treatment. disease activity assessed using sledai-2k with responder index - 50, quality of life assessed using sleqol v2, and hfr was performed for the non-responder group. the study will be conducted in alexandria university hospitals in compliance with the declaration of helsinki; the ethical committee of the investigator's faculty will be requested to approve the protocol and the patients will be requested to give informed consent.

Eligibility criteria:
inclusion criteria: * systemic lupus erythematosus in activity exclusion criteria: * end stage renal disease, other renal replacement therapy

Keywords: hemodiafiltration with endogenous re infusion immune adsorption in lupus nephritis
efficacy of plasmapheresis in patients of drug-induced liver injury (dili) with underlying chronic liver disease

Conditions: Drug Induced Liver Injury; Chronic Liver Disease

Summary: dili is an underdiagnosed and under appreciated causal or contributing factor to liver injury. dili can mimics features of the entire spectrum of acute and chronic liver disease. asia-pacifc region is characterized by two unique features; the high prevalence of tuberculosis (tb) in the population and the ubiquitous use of traditional and complimentary medicines.current definition of hy's law presents significant difficulties when dealing with patients with preexisting cld in clinical trials. hallmark of the hepatic manifestation in these patients is hyperbilirubinemia and coagulopathy rather than alt elevation.

study design single-center, non-blinded, parallel group, randomized controlled trial. allocation ratio between two groups: 1:1. study population: adults aged 18-75 years with previously known or unknown underlying cld diagnosis of dili-based causality of assessment by recam. severe dili with bilirubin \> 12mg/dl or inr\>2, s.bili \>5 mg/dl consent to participate in the study (based on biopsy, imaging or clinical criteria). study design: rct study period: 1 year sample size: 96 intervention: patients after screening for all exclusion criteria will be randomized into either the standard treatment group or the plasma exchange group. monitoring and assessment: all patients would undergo vital and baseline parameter screening before randomization. based on randomization they will receive either steroid or plasma exchange followed by steroid.

Eligibility criteria:
inclusion criteria: 1. adults aged 18-75 years with previously known or unknown underlying cld. 2. diagnosis of dili based causality of assessment by recam. 3. severe dili with bilirubin \> 12mg/dl or inr\>2, s.bili \>5 mg/dl. 4. consent to participate in the study (based on biopsy/imaging/or clinical criteria). exclusion criteria: 1. active infection 2. contraindications to plasmapheresis (e.g., severe coagulopathy, hemodynamic instability, patients with sepsis, shock, poor p/f ratio). 3. pregnant or breastfeeding women. 4. hcc or any malignancy 5. ugi bleed, uncontrolled he 6. option ltx being considered 7. s. creatinine \> 2mg/dl 8. dili alf 9. alcoholic hepatitis
current therapy in primary sjogren's syndrome

Conditions: Primary Sjögren's Syndrome (pSS)

Summary: purpose:the aim of the study was to investigate the effectiveness of interferential current therapy on salivary gland function in primary sjogren's syndrome (pss). methods:thirty six pss were included in the study. patients were randomly divided into 2 groups (group 1 (treatment group) n=18; group ii (placebo group) n=18). salivary flow rate measurement (sfrm), oral health-related quality of life-united kingdom questionnaire (ohrqol-uk), oral health impact profile-14 (ohip-14), health assessment questionnaire (haq), beck anxiety inventory (bai), beck depression inventory (bdi), pittsburgh sleep quality index (psqi) and short form-36 (sf-36) were used for evaluation. all evaluations were done pre-, posttreatment, at 3. month, at 6. month and at 9. month. clinical pilates exercises and interferential current therapy were applied to group i while clinical pilates exercises and interferential current therapy as placebo was applied to group ii. all treatments were given three times a week for 8 weeks.


Eligibility criteria:
inclusion criteria: * to be diagnosed with pss according to the 2016 european league against rheumatism american / college of rheumatology classification criteria, * to be in the 3rd and 4th grade according to the chisholm-mason grading system, * be in the age range of 25-65 years, * to be stable on drug use for at least 3 months or longer, (f) to have agreed to participate in the study. exclusion criteria: * to use antipsychotic, antidepressant, antihypertensive, medical agent for parkinson's, * presence of viral infection, * presence of diabetes mellitus, * receiving head and neck radiotherapy/chemotherapy, * having a head and neck malignancy, * having undergone head and neck surgery, * presence of dehydration, * pregnancy, * using cigarettes and alcohol, * cognitive problems that affect cooperation, * having any other disease that may affect their functions.
study of dac combined with haag regimen in newly diagnosed aml patients older than 60

Conditions: Acute Myeloid Leukemia; Induction Chemotherapy

Summary: the purpose of this study is to evaluate the safety and efficacy of dac combined with haag regimen in the induction treatment of newly diagnosed aml patients older than 60 years.

this is a phase 3, open label, single arm, multi-center study in elderly newly diagnosed aml patients. the patients will receive dac combined with haag in the induction treatment.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed aml according to the who (2016) classification of acute myeloid leukemia. 2. 60-79 years old. 3. ecog score: 0-3. 4. no history of previous chemotherapy or target therapy. 5. provide informed consent. exclusion criteria: 1. patients have acute promylocytic leukemia or chronic myeloid leukemia in blast crisis. 2. patients with another malignant disease. 3. patients with uncontrolled active infection. 4. patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade iii/iv cardiovascular dysfunction according to the new york heart association classification. 5. patients with aspartate aminotransferase or glutamic-pyruvic transaminase \> 3x upper limit of normal or bilirubin \> 2.0 mg/dl. 6. patients with creatinine clearance rate \< 50ml/min. 7. patients with active hepatitis b or hepatitis c infection. 8. patients with hiv infection. 9. patients with other commodities that the investigators considered not suitable for the enrollment.

Keywords: decitabine, haag, aml
second look laparoscopy in colorectal cancer

Conditions: Colorectal Cancer

Summary: the purpose of this study is to evaluate whether a second-look laparoscopy, followed by peritonectomy, hyperthermic intraperitoneal chemotherapy (hipec) or systemic chemotherapy in case of peritoneal carcinosis, improves the overall survival of patients who have had radical resection of mucinous colorectal cancer.

patients will be entered into the study after radical resection of mucinous colorectal cancer, and reevaluated by ct scan after 6 months. patients with no evidence of disease will be randomized to receive either standard follow up, or to have a second look laparoscopy to evaluate for peritoneal carcinosis. after laparoscopy, those patients who do not have peritoneal carcinosis will continue with standard follow up. patients with peritoneal carcinosis diagnosed by laparoscopy will be treated according to their peritoneal carcinosis index (pci). for patients with pci \> 20, systemic chemotherapy will be given according to italian association of medical oncology (aiom) guidelines. patients with pci \< 20 will undergo peritonectomy and then receive intravenous chemotherapy immediately followed by hipec.

Eligibility criteria:
inclusion criteria: * histologic diagnosis colorectal adenocarcinoma * mucinous histotype * stage i-iii * radical (r0) surgical resection of primary tumor * ct scan with contrast showing no evidence of disease recurrence 6 months after primary surgery * age ≥ 18 ≤ 65 years * performance status ecog ≤1 * normal hepatic, renal and hematologic function * adjuvant chemotherapy permitted * signed informed consent exclusion criteria: * residual disease after surgical resection of primary tumor * distant metastasis * active systemic infection * chronic cardiovascular illness that would contraindicate abdominal dilatation with pneumoperitoneum * concomitant or previous malignancy with 5 years of surgical resection of primary tumor (except for adequately treated non-melanoma skin cancer and in situ cervical cancer) * pregnancy or lactation * refusal or incapability of providing informed consent * impossibility of complying with study schedules and follow-up

Keywords: hyperthermic chemotherapy intraperitoneal chemotherapy second-look laparoscopy peritoneal carcinosis mucinous colorectal cancer
safety and tolerability of leo 138559 in healthy subjects and subjects with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the primary objective of this trial is to investigate the safety and tolerability of leo 138559 in healthy subjects and subjects with moderate to severe atopic dermatitis. the secondary objective of this trial is to study the pharmacokinetics and pharmacodynamics following administration of leo 138559 to healthy subjects and subjects with moderate to severe atopic dermatitis. healthy subjects will be exposed to 7 different dose regimens of leo 138559 (one dose regimen per subject). subjects with moderate to severe atopic dermatitis will be exposed to 2 different dose regimens of leo 138559 (one dose regimen per subject).


Eligibility criteria:
inclusion criteria: for healthy subjects and subjects with atopic dermatitis: * males and females without childbearing potential. * age between 18 and 55, inclusive. * body mass index between 18 and 32 kg/m2, inclusive. * healthy apart from atopic dermatitis for the subjects presenting the disease. for subjects with atopic dermatitis only: * history of atopic dermatitis for more than 6 months. * female subjects with childbearing potential and male subjects with female partners with childbearing potential using highly effective contraception from start of the trial and until a period after the last administered dose of trial drug. exclusion criteria: for healthy subjects and subjects with atopic dermatitis: * any significant disease detected prior to enrolment. * subjects who are still participating in a clinical trial or who have participated in a clinical trial within 3 months prior to enrolment or within 5 times of the half-life of the experimental therapy, whichever is longer. * skin diseases that may interfere with the diagnosis of atopic dermatitis or assessment of the treatment. * use of tanning beds or phototherapy within 6 weeks prior to enrolment. * subjects with atopic dermatitis requiring more than 3 bleach baths from 4 weeks prior to screening until end of trial. * blood pressure or pulse rate outside of the normal range. for subjects with atopic dermatitis only: * initiation of treatment of atopic dermatitis with prescription emollients during the screening period.
sequelae of covid-19 with focus on exercise capacity and underlying mechanisms

Conditions: Patients Post-COVID-19; Controls

Summary: the project is designed as a cross-sectional study and aims to examine long-term consequences of coronavirus disease 2019 (covid-19) for selected bio-behavioural parameters while taking the disease course severity into account.


Eligibility criteria:
inclusion criteria: * tested positive for sars-cov-2 using antigen- or pcr tests within the last 18 months * previous hospitalisation due to covid-19 * fully vaccinated (only for controls) exclusion criteria: * inability to follow the study procedures (e.g. due to language barriers, psychological disorders, dementia, etc.), * known pregnancy or lactating women, * presence of any contraindications for exercising until maximum exhaustion, including insufficient blood pressure control (systolic \>170 mmhg, diastolic \>100 mmhg), ongoing cancer treatment, unstable angina pectoris, uncontrolled bradyarrhythmia or tachyarrhythmia, severe uncorrected valvular heart disease, clinically relevant acute infection, any form of musculoskeletal injury, * participating in any interventional clinical trial within the last four weeks, * previous participation in the current study * history of symptomatic covid-19 (only for controls)

Keywords: sars-cov-2 coronavirus sequelae exercise intolerance cardiopulmonary exercise testing
occurrence, diagnosis and treatment of neck and back pain in helicopter pilots.

Conditions: Low Back Pain; Neck Pain; Muscular Atrophy

Summary: the purpose of this project is to investigate the occurrence of neck and back pain in a population of commercial helicopter pilots, and investigate factors related to the profession that can cause these problems. the project has a biological approach assessing the supporting and stabilizing muscles (multifidus) in pilots with chronic back and neck ailments. pilots with low back problems are invited to a controlled intervention trial to investigate whether one can achieve improved spinal health with a rigid training régime. primary trial outcome is improved neck and back multifidus muscles pathology and function as assessed by the extent of fat infiltration -as visualized on mri - and the volume and ability of the lumbar multifidus muscles to contract as shown with ultrasound. the perceived effect on spinal health with sick leave frequency is also evaluated.


Eligibility criteria:
inclusion criteria: * pilots must experience low back pain in at least 1 of 3 flights or * pilots must have at least 2 episodes of low back pain of at least 24 hours duration over the last 12 months. each episode is separated with at least one painfree month before and after each episode, or * pilots may have had more than 3 sick leaves due to low back pain over the last 5 years exclusion criteria: * contraindications for physical training/activity
safety and efficacy of emergent tavi in patients with severe as

Conditions: Aortic Valve Stenosis; Transcatheter Aortic Valve Implantation; Emergencies

Summary: this is a single-centre, prospective, observational cohort study focusing on of patients suffering severe aortic valve stenosis (as) undergoing emergent transcatheter aortic valve implantation (tavi). as patients undergoing emergent tavi always have complicated clinical situations. therefore, the aims of the study are to collect the incidence and outcomes of emergent tavi in patients with severe symptomatic as, to assess the safety and effectiveness of emergency tavi system for severe as, and to describe a more practical evidence of emergency tavi system in severe as patients.


Eligibility criteria:
inclusion criteria: 1. every patient that diagnosed with severe aortic valve stenosis (evaluated by echocardiography: peak transaortic valve blood flow rate ≥4.0m/s, or mean transaortic valve pressure gradient ≥40mmhg (≥5.32kpa), or aortic valve area \<0.8cm2, or ava\<0.5cm2/m2); 2. every patient that 1) required cardiopulmonary resuscitation due to cardiac arrest, or requiring external chest compressions during surgery (salvage), 2) or has ongoing, refractory (difficult, complicated, and/or unmanageable) unrelenting cardiac compromise, with or without hemodynamic instability, and not responsive to any form of therapy except cardiac surgery (sts/acc tvt defined "urgent status"), 3) or required urgent procedure during same hospitalization in order to minimize chance of further clinical deterioration (examples include, but are not limited to, worsening, sudden chest pain, heart failure, acute myocardial infarction, anatomy, intra-aortic balloon pump, unstable angina with intravenous nitroglycerin or rest angina) (sts/acc tvt defined "urgent status"); 3. every patient that has been informed of the objectives of the study, agreed to participate, has signed the approved consent form, and was willing to accept all relevant examinations and clinical follow-up. exclusion criteria: 1. anatomically, the approach or aortic root is not suitable for transcatheter aortic valve implantation (tavi). 2. anatomical morphology or vascular diseases affecting the device approach. 3. left ventricular outflow tract obstruction. 4. primary dilated cardiomyopathy. 5. the echocardiogram indicates the presence of left ventricular thrombus. 6. cannot tolerate anticoagulation and antiplatelet therapy. 7. are allergic or resistant to nickel titanium alloys. 8. active infective endocarditis, or other active infections affecting the effect of tavi. 9. severe disabling alzheimer's disease. 10. life expectancy\< 6 months. 11. other conditions (examples include poor compliance of patients and families) considered by the investigator to be inappropriate for participation in this clinical trial.